logo
Legionnaires' Disease Sickens 22 in New York. Here's What to Know.

Legionnaires' Disease Sickens 22 in New York. Here's What to Know.

New York Times5 days ago
At least 22 people have fallen ill, including one person who has died, from Legionnaires' disease in New York City over the last two weeks, according to the city's health department.
City health officials believe that the people most likely became ill after breathing in bacteria sprayed from a cooling tower in central Harlem. The city health department said in a news release on Wednesday that it was testing the cooling towers in the area and continuing to investigate the outbreak.
Legionnaires' is a severe form of pneumonia that can cause a cough, shortness of breath and fever. The risk is low for most people, said Dr. Celia Quinn, the deputy commissioner of the division of infectious diseases at the New York City Department of Health and Mental Hygiene, but people who live or work around the affected area should see a health care provider immediately if they develop flulike symptoms. There will most likely be additional cases linked to this cluster, Dr. Quinn added.
The city health department said that it was safe to continue drinking water, bathing, showering, cooking and using air-conditioning.
Around 6,000 cases of Legionnaires' are reported each year in the United States, but scientists think the disease is underdiagnosed because it can be hard to distinguish from other types of pneumonia or respiratory issues. And cases have been rising over the last two decades. There is no clear reason for the increase, but some researchers have pointed to aging water systems, inadequate maintenance of systems, rising water temperatures and greater awareness of the disease.
And cases tend to pop up during the summer months, as more buildings use cooling towers for air conditioning.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CDC warns travelers about chikungunya cases in China as global infections hit 240,000
CDC warns travelers about chikungunya cases in China as global infections hit 240,000

Yahoo

time10 minutes ago

  • Yahoo

CDC warns travelers about chikungunya cases in China as global infections hit 240,000

U.S. health officials are cautioning travelers about a mosquito-borne illness being transmitted in parts of Asia, South America, Africa and the Indian Ocean. Across the globe, the chikungunya virus has sparked 240,000 cases and 90 deaths in 2025, according to the European Centre for Disease Prevention and Control. The virus, which is infecting people through bites from Aedes mosquitoes, has been spreading in China's Guangdong province this summer. Health officials reported the area has seen over 7,000 confirmed cases since June. The U.S. Centers for Disease Control and Prevention (CDC) this month issued a travel notice for the Guangdon province in China, encouraging travelers to practice enhanced precautions. The agency issued the same notices for other countries where outbreaks have been reported, including Bolivia, Kenya, Madagascar, Mauritius, Mayotte, Réunion, Somalia and Sri Lanka. The CDC is also asking U.S. residents to exercise caution when visiting the following countries, which have not yet reported an outbreak but are at elevated risk of exposure: Brazil, Colombia, Mexico, India, Pakistan, Philippines, Thailand and Nigeria. According to the World Health Organization (WHO), 5.6 billion people are at risk of arboviral diseases such as chikungunya. Other widespread arboviruses impacting humans include dengue, Zika and yellow fever. What are the symptoms of chikungunya? Symptoms of the disease include fever, joint pain and swelling, headache, muscle pain and rash, according to the CDC. How long does infection last? The illness typically lasts between two to 12 days after infection. Some patients can experience extreme symptoms and the virus can be fatal. Elderly people, newborns and individuals with underlying medical conditions are at higher risk of medical intervention. Severe complications, including cardiovascular, neurological and multiorgan involvement, may require intensive medical care, according to the WHO. However, more than half of patients will experience symptoms commonly associated with a fever. What treatments are available? There are no known antiviral treatments for the illness. Medications can be used to manage pain and fever. Two chikungunya vaccines have received regulatory approval but are not widely available. In May, federal officials recommended pausing a vaccine in the United States after reports of serious adverse events. The illness was first discovered in Tanzania in 1952, with outbreaks being reported in Africa and Asia, according to the WHO. Since then, the virus has been transmitted to 119 countries. Last year, more than 620,000 and 213 deaths were reported globally, according to the European Centre for Disease Prevention and Control. In what was then dubbed the largest documented outbreak of chikungunya, an estimated several hundred thousand people were affected by "explosive" outbreaks of the virus in the Indian Ocean islands and India, according to a 2008 study. It's estimated that about 60 percent of regional populations were exposed. CDC issues travel notice for Americans The CDC issued a travel warning on Friday, Aug. 1, advising U.S. residents to take enhanced precautions when traveling to China. Most of the country's cases have been reported in the city of Foshan. Last month, Chinese officials held a national conference to discuss treatments for and prevention of the illness. Authorities agreed to continue monitoring the situation and issue early warnings through multiple channels to prevent further spreading, according to China's National Health Commission. Michelle Del Rey is a trending news reporter at USA TODAY. Contact her at mdelrey@ This article originally appeared on USA TODAY: Chikungunya virus cases reported in China prompt CDC travel notice Solve the daily Crossword

Linda Yaccarino joins health tech platform eMed as CEO after leaving X
Linda Yaccarino joins health tech platform eMed as CEO after leaving X

TechCrunch

time11 minutes ago

  • TechCrunch

Linda Yaccarino joins health tech platform eMed as CEO after leaving X

Linda Yaccarino's next role after departing X as CEO will be another chief executive role at eMed Population Health, an AI startup building a tech platform for patients using GLP-1s. Yaccarino was a longtime advertising executive at NBCUniversal, but left to join X as CEO for two years, where she managed to have a positive impact on the social network's troubled ad revenue model, despite her and Elon Musk's shared approach to minimizing content moderation. Though Yaccarino does not have experience in health tech, eMed said in a press release that they sought her out for her 'undeniable ability to negotiate new partnerships' — it certainly also helps that her tenure at X made her well-known in the tech world, drawing more eyes toward the startup. eMed previously produced a tech platform that was designed to be used with at-home COVID-19 rapid antigen tests, guiding users through the process of administering these tests properly. Now, eMed is focused on GLP-1s, the class of drugs like Ozempic, which can be used for both weight management and treatment of type II diabetes. 'To be a leader in today's healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry,' Yaccarino said in a press release. 'We are very well-positioned to be that tenacious leader, striving toward our ultimate goal of improving global healthcare outcomes through our groundbreaking services and platforms.'

From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health
From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health

Yahoo

time40 minutes ago

  • Yahoo

From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health

Fellow Health just raised $24 million in a Series B funding round, bringing its cash haul across multiple offerings to $48 million. The San Leandro, California startup advances male reproductive health through "patient-centric testing solutions" and plans to use the capital infusion to expand its mail-in semen analysis services. Fellow Health provides clinical grade, mail-in analysis of male fertility and post-vasectomy status while committing to "privacy, convenience and timely results." Italready has a network of more than 2,500 fertility and urology providers nationwide and wants to "deepen its footprint" through expansion into employer-sponsored fertility benefits and "broader access initiatives." Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— led the latest funding round, in which asset management firm Forest Road participated for the first time. Forest Managing Partner of Life Sciences Bill Burkoth will join Fellow's board as part of the financing deal. Other investors since the initial round include Labcorp Venture Fund, Genoa Ventures and Mantis Venture Capital. "Fellow Health is exactly the kind of company we look for – operating in a large, overlooked market that's long overdue for disruption," Burkoth said in a statement. "With over 50,000 test results delivered so far this year, they've proven there is real demand for a better patient experience." Live sperm gets counted in fertility analysis. These cells can live three to days within the cervix, uterus and fallopian tubes, but usually die in under an hour outside a woman's body. The mail-in service addresses this time bomb with a "preservation solution designed to stabilize your sample and a gel pack that helps maintain a moderate temperature during transit." Mail-in post-vasectomy testing is less time critical because it counts both living and dead sperm. Trending: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can Fellow Health points to studies backing up its claim that it can provide "results on par with traditional one-hour semen analysis when analyzing samples received within 52 hours of when they were produced." It sells both testing products and a cryopreservation service without a doctor's prescription at its website. 'Male reproductive health should not be reactive or inaccessible,' Fellow CEO Brian Hogan said in the statement. 'We are on track to deliver over 40% year-over-year revenue growth, with a path to profitability in our fertility segment by 2026. This investment allows us to scale that vision and support both patients and providers with modern tools that work.'However, Fellow Health faces stiff competition in the male fertility space that could impact this optimistic revenue outlook. Rival Posterity Health booked $13 million in Series A funding earlier this year. The company partnered with Mark Cuban Cost Plus Drug Company in 2023 to provide access to treatments for infertility, sexual dysfunction and low testosterone. A year earlier, American telehealth provider Ro bought Dadi, another male fertility and sperm testing startup. Its reproduction preservation service for men looks like a direct competitor to Fellow Health's family of products. Ro has also made a splash in women's health, acquiring Modern Fertility in 2021. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store